In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

investigating the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide on the total cardiovascular (CV) events in patients with CV disease (CVD) who are either overweight or ...

Semaglutide was initially approved under the brand name Ozempic for Type 2 diabetes, while the brand name Wegovy is only approved for weight loss. Here, we’ll compare tirzepatide (Zepbound ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ... on about 3,600 customer reviews, it has an A+ rating ...